A Phase 1/2 Randomized, Double-blind, Placebo-controlled, Single-dose Study of FX-322 Administered by Intratympanic Injection in Adults With Stable Sensorineural Hearing Loss
Phase of Trial: Phase I/II
Latest Information Update: 14 Aug 2018
At a glance
- Drugs FX 322 (Primary)
- Indications Sensorineural hearing loss
- Focus Therapeutic Use
- Sponsors Frequency Therapeutics
- 08 Aug 2018 Status changed from planning to recruiting.
- 22 Feb 2018 New trial record
- 15 Feb 2018 According to a Frequency Therapeutics media release, this trial is anticipated to begin in 2018.